NASDAQ:DTIL Precision BioSciences (DTIL) Stock Price, News & Analysis $5.04 -0.09 (-1.75%) Closing price 04:00 PM EasternExtended Trading$5.07 +0.03 (+0.50%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Precision BioSciences Stock (NASDAQ:DTIL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Precision BioSciences alerts:Sign Up Key Stats Today's Range$5.00▼$5.1850-Day Range$4.13▼$5.1552-Week Range$3.61▼$11.09Volume64,651 shsAverage Volume322,044 shsMarket Capitalization$59.41 millionP/E RatioN/ADividend YieldN/APrice Target$47.00Consensus RatingBuy Company Overview Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. Read More Precision BioSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreDTIL MarketRank™: Precision BioSciences scored higher than 77% of companies evaluated by MarketBeat, and ranked 236th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPrecision BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePrecision BioSciences has received no research coverage in the past 90 days.Read more about Precision BioSciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Precision BioSciences are expected to grow in the coming year, from ($1.23) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precision BioSciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precision BioSciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecision BioSciences has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Precision BioSciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.75% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Precision BioSciences has recently increased by 17.59%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrecision BioSciences does not currently pay a dividend.Dividend GrowthPrecision BioSciences does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.99 Percentage of Shares Shorted14.75% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Precision BioSciences has recently increased by 17.59%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 6 people have searched for DTIL on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat Follows2 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Precision BioSciences insiders have sold 807.12% more of their company's stock than they have bought. Specifically, they have bought $6,963.00 in company stock and sold $63,163.00 in company stock.Percentage Held by InsidersOnly 4.50% of the stock of Precision BioSciences is held by insiders.Percentage Held by InstitutionsOnly 37.99% of the stock of Precision BioSciences is held by institutions.Read more about Precision BioSciences' insider trading history. Receive DTIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DTIL Stock News HeadlinesHC Wainwright Issues Positive Estimate for DTIL EarningsAugust 16, 2025 | americanbankingnews.comPrecision BioSciences Reports Promising Phase 1 Trial ResultsAugust 14, 2025 | theglobeandmail.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.August 26 at 2:00 AM | Investors Alley (Ad)Precision BioSciences Reports Significant Quarterly LossAugust 12, 2025 | theglobeandmail.comDTIL Revenue Drops 99%August 7, 2025 | fool.comPrecision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7, 2025 | businesswire.comPrecision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis BAugust 6, 2025 | businesswire.comPrecision BioSciences to Report Second Quarter 2025 Results on August 7, 2025August 4, 2025 | businesswire.comSee More Headlines DTIL Stock Analysis - Frequently Asked Questions How have DTIL shares performed this year? Precision BioSciences' stock was trading at $3.81 at the beginning of 2025. Since then, DTIL stock has increased by 33.9% and is now trading at $5.10. How were Precision BioSciences' earnings last quarter? Precision BioSciences, Inc. (NASDAQ:DTIL) posted its earnings results on Thursday, August, 7th. The company reported ($2.13) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $2.04. The company earned $0.02 million during the quarter, compared to the consensus estimate of $6.27 million. Precision BioSciences had a negative net margin of 6,205.79% and a negative trailing twelve-month return on equity of 176.47%. When did Precision BioSciences' stock split? Precision BioSciences's stock reverse split on Wednesday, February 14th 2024.The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Precision BioSciences IPO? Precision BioSciences (DTIL) raised $126 million in an initial public offering on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO. Who are Precision BioSciences' major shareholders? Precision BioSciences' top institutional shareholders include Corient Private Wealth LLC (0.86%), Geode Capital Management LLC (0.70%) and Bridgeway Capital Management LLC (0.53%). Insiders that own company stock include J Jefferson Smith, John Alexander Kelly, Melinda Brown, Geno J Germano, Dario Scimeca and Alan List. View institutional ownership trends. How do I buy shares of Precision BioSciences? Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Precision BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precision BioSciences investors own include Editas Medicine (EDIT), Luminar Technologies (LAZR), CRISPR Therapeutics (CRSP), Enovix (ENVX), Nokia (NOK) and Ginkgo Bioworks (DNA). Company Calendar Last Earnings8/07/2025Today8/26/2025Next Earnings (Estimated)11/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DTIL CIK1357874 Webwww.precisionbiosciences.com Phone(919) 314-5512FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Price Target for Precision BioSciences$47.00 High Price Target$60.00 Low Price Target$34.00 Potential Upside/Downside+816.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($8.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$7.17 million Net Margins-6,205.79% Pretax Margin-6,205.79% Return on Equity-176.47% Return on Assets-69.05% Debt Debt-to-Equity Ratio0.66 Current Ratio5.18 Quick Ratio5.18 Sales & Book Value Annual Sales$1.26 million Price / Sales47.95 Cash FlowN/A Price / Cash FlowN/A Book Value$6.87 per share Price / Book0.75Miscellaneous Outstanding Shares11,787,000Free Float11,316,000Market Cap$60.47 million OptionableNo Data Beta1.52 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:DTIL) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.